|
Approach
|
DENV inoculation
|
Mouse
|
Outcome
|
Reference
|
|---|
|
Monoclonal anti-NS1 Abs
|
DENV2 (NGC) 100 IC50 i.c.
|
BALB/c
|
50-93% Survival
|
[135]
|
|
DNA vaccine:
|
DENV2 (PL046)
|
C3H/HeN
|
pD2NS1: 50% Survival
|
[136]
|
|
pD2NS1
|
107 PFU i. p.
|
50% Morbidity
|
|
pD2NS1 + pIL12
|
pD2NS1 + pIL12: 80% Survival
|
|
20% Morbidity
|
|
DNA vaccine: pcTPANS1
|
DENV2 (NGC)
|
BALB/c
|
50% Survival
|
[137]
|
|
4,32 log10PFU i.c.
|
|
DNA vaccine: pcTPANS1*
|
DENV2 (NGC)
|
BALB/c
|
pcTPANS1: 96.7% Survival
|
[138]
|
|
pcENS1**
|
4,32 log10PFU i.c.
|
10%Morbidity
|
|
pcEN1: 86.7% Survival
|
|
27% Morbidity
|
|
Vaccinia Virus:
|
DENV4 (H241)
|
BALB/c
|
67% Survival
|
[139]
|
|
vNS1-15% NS2a
|
100IC50 i.c.
|
|
rNS1 + CFA (adjuvant)
|
DENV2 (NGC)
|
BALB/c
|
88% Survival
|
[77]
|
|
Lethal dose i.c.
|
18% morbidity
|
|
rNS1 + LTG33D (adjuvant)
|
DENV2 (NGC)
|
BALB/c
|
50% Survival
|
[140]
|
|
4,32 log10PFU i.c.
|
80% Morbidity
|
- *TPA human tissue plasminogen activator, a secretory signal sequence.
- **pcENS1: encoding the C-terminal E protein plus the NS1 region.
- i.c intracerebal, i.p intraperitoneal.
